GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InNexus Biotechnology Inc (GREY:IXSBF) » Definitions » Capex-to-Revenue

InNexus Biotechnology (InNexus Biotechnology) Capex-to-Revenue : 0.00 (As of Mar. 2011)


View and export this data going back to . Start your Free Trial

What is InNexus Biotechnology Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

InNexus Biotechnology's Capital Expenditure for the three months ended in Mar. 2011 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2011 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


InNexus Biotechnology Capex-to-Revenue Historical Data

The historical data trend for InNexus Biotechnology's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InNexus Biotechnology Capex-to-Revenue Chart

InNexus Biotechnology Annual Data
Trend Jun01 Jun02 Jun03 Jun04 Jun05 Jun06 Jun07 Jun08 Jun09 Jun10
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.54 55.93 1,155.00 - -

InNexus Biotechnology Quarterly Data
Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InNexus Biotechnology's Capex-to-Revenue

For the Biotechnology subindustry, InNexus Biotechnology's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InNexus Biotechnology's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InNexus Biotechnology's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where InNexus Biotechnology's Capex-to-Revenue falls into.



InNexus Biotechnology Capex-to-Revenue Calculation

InNexus Biotechnology's Capex-to-Revenue for the fiscal year that ended in Jun. 2010 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.012) / 0
=N/A

InNexus Biotechnology's Capex-to-Revenue for the quarter that ended in Mar. 2011 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InNexus Biotechnology  (GREY:IXSBF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


InNexus Biotechnology Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of InNexus Biotechnology's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


InNexus Biotechnology (InNexus Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
1055 West Georgia Street, 1500 Royal Centre, Vancouver, BC, CAN, V6E 4N7
InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

InNexus Biotechnology (InNexus Biotechnology) Headlines

No Headlines